The DOI matches its Crossref record; 244 of the 244 references it cites were found in a registry or an index.
Anakinra Therapy for Non-cancer Inflammatory Diseases
Open accessAbstract
Interleukin-1 (IL-1) is the prototypic inflammatory cytokine: two distinct ligands (IL-1α and IL-1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory mediators, including prostaglandins, cytokines and chemokines. IL-1α is constitutively present in endothelial and epithelial cells whereas IL-1β is inducible in myeloid cells and released following cleavage by caspase 1. Over the past 30 years, IL-1-mediated inflammation has been established in a broad spectrum of diseases, ranging from rare autoinflammatory diseases to common conditions such as gout and rheumatoid arthritis, type 2 diabetes, atherosclerosis, and acute myocardial infarction. Blocking IL 1 entered the clinical arena with anakinra, the recombinant form of the naturally occurring IL 1 Receptor antagonist (IL 1Ra); IL 1Ra prevents the binding of IL 1α as well as IL 1β to IL 1R1. Quenching IL 1-mediated inflammation prevents the detrimental consequences of tissue damage and organ dysfunction. Although anakinra is presently approved for the treatment of rheumatoid arthritis and cryopyrin-associated periodic syndromes, off-label use of anakinra far exceeds its approved indications. Dosing of 100 mg of anakinra subcutaneously provides clinically evident benefits within days and for some diseases, anakinra has been used daily for over 12 years. Compared to other biologics, anakinra has an unparalleled record of safety and opportunistic infections, particularly Mycobacterium tuberculosis are rare, even in populations at risk for reactivation of latent infections. Because of this excellent safety profile and relative short duration of action, anakinra can also be used as a diagnostic tool for undefined diseases mediated by IL 1. Although anakinra is presently in clinical trials to treat cancer, this review focuses on anakinra treatment of acute as well as chronic inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
Self-citationNLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
Hornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., & Latz, E. (2008) · Nature Immunology · doi:10.1038/ni.1631 · Cited by 3,065
The Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Self-citationMcDermott, M. F., Aksentijevich, I., Galon, J., McDermott, E. M., Ogunkolade, B. W., Centola, M., Mansfield, E., Gadina, M., Karenko, L., Pettersson, T., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80721-7 · Cited by 1,408
Masters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) · Nature Immunology · doi:10.1038/ni.1935 · Cited by 1,330
Leung, C. C., Yu, I. T. S., & Chen, W. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60235-9 · Cited by 1,193
Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor
Hannum, C. H., Wilcox, C. J., Arend, W. P., Joslin, F. G., Dripps, D. J., Heimdal, P. L., Armes, L. G., Sommer, A., Eisenberg, S. P., & Thompson, R. C. (1990) · Nature · doi:10.1038/343336a0 · Cited by 1,122
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Eisenberg, S. P., Evans, R. J., Arend, W. P., Verderber, E., Brewer, M. T., Hannum, C. H., & Thompson, R. C. (1990) · Nature · doi:10.1038/343341a0 · Cited by 1,088
Nucleotide sequence of human monocyte interleukin 1 precursor cDNA.
Auron, P. E., Webb, A. C., Rosenwasser, L. J., Mucci, S. F., Rich, A., Wolff, S. M., & Dinarello, C. A. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.24.7907 · Cited by 1,042
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist
Aksentijevich, I., Masters, S. L., Ferguson, P. J., Dancey, P., Frenkel, J., van Royen-Kerkhoff, A., Laxer, R., Tedgård, U., Cowen, E. W., Pham, T.-H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807865 · Cited by 987
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
Bresnihan, B., Alvaro-Gracia, J. M., Cobby, M., Doherty, M., Domljan, Z., Emery, P., Nuki, G., Pavelka, K., Rau, R., Rozman, B., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199812)41:12<2196::aid-art15>3.0.co;2-2 · Cited by 981
Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation
Guarda, G., Braun, M., Staehli, F., Tardivel, A., Mattmann, C., Förster, I., Farlik, M., Decker, T., Du Pasquier, R. A., Romero, P., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.006 · Cited by 933
Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
Pascual, V., Allantaz, F., Arce, E., Punaro, M., & Banchereau, J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050473 · Cited by 922
Ridker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., Thuren, T., Glynn, R. J., Ridker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32814-3 · Cited by 919
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869
Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001402 · Cited by 867
Self-citationIL-37 is a fundamental inhibitor of innate immunity
Nold, M. F., Nold-Petry, C. A., Zepp, J. A., Palmer, B. E., Bufler, P., & Dinarello, C. A. (2010) · Nature Immunology · doi:10.1038/ni.1944 · Cited by 849
Self-citationA guiding map for inflammation
Netea, M. G., Balkwill, F., Chonchol, M., Cominelli, F., Donath, M. Y., Giamarellos-Bourboulis, E. J., Golenbock, D., Gresnigt, M. S., Heneka, M. T., Hoffman, H. M., et al. (2017) · Nature Immunology · doi:10.1038/ni.3790 · Cited by 831
Self-citationCloning and expression of murine interleukin-1 cDNA in Escherichia coli
Lomedico, P. T., Gubler, U., Hellmann, C. P., Dukovich, M., Giri, J. G., Pan, Y.-C. E., Collier, K., Semionow, R., Chua, A. O., & Mizel, S. B. (1984) · Nature · doi:10.1038/312458a0 · Cited by 816
Stienstra, R., Joosten, L. A. B., Koenen, T., van Tits, B., van Diepen, J. A., van den Berg, S. A. A., Rensen, P. C. N., Voshol, P. J., Fantuzzi, G., Hijmans, A., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.11.011 · Cited by 676
Interleukin-1–Receptor Antagonist in the Muckle–Wells Syndrome
Hawkins, P. N., Lachmann, H. J., & McDermott, M. F. (2003) · New England Journal of Medicine · doi:10.1056/nejm200306193482523 · Cited by 654
Cohen, S., Hurd, E., Cush, J., Schiff, M., Weinblatt, M. E., Moreland, L. W., Kremer, J., Bear, M. B., Rich, W. J., & McCabe, D. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10141 · Cited by 638
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease
Diamond, E. L., Dagna, L., Hyman, D. M., Cavalli, G., Janku, F., Estrada-Veras, J., Ferrarini, M., Abdel-Wahab, O., Heaney, M. L., Scheel, P. J., et al. (2014) · Blood · doi:10.1182/blood-2014-03-561381 · Cited by 586
Self-citationQuartier, P., Allantaz, F., Cimaz, R., Pillet, P., Messiaen, C., Bardin, C., Bossuyt, X., Boutten, A., Bienvenu, J., Duquesne, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.134254 · Cited by 558
Chae, J. J., Wood, G., Masters, S. L., Richard, K., Park, G., Smith, B. J., & Kastner, D. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602081103 · Cited by 554
Familial and Acquired Hemophagocytic Lymphohistiocytosis
Janka, G. E. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-041610-134208 · Cited by 549
Hirsch, L. J., Gaspard, N., van Baalen, A., Nabbout, R., Demeret, S., Loddenkemper, T., Navarro, V., Specchio, N., Lagae, L., Rossetti, A. O., et al. (2018) · Epilepsia · doi:10.1111/epi.14016 · Cited by 540
Dinarello, C. A., Ikejima, T., Warner, S. J. C., Orencole, S. F., Lonnemann, G., Cannon, J. G., & Libby, P. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.6.1902 · Cited by 537
Self-citationChevalier, X., Goupille, P., Beaulieu, A. D., Burch, F. X., Bensen, W. G., Conrozier, T., Loeuille, D., Kivitz, A. J., Silver, D., & Appleton, B. E. (2009) · Arthritis Care & Research · doi:10.1002/art.24096 · Cited by 533
Solovic, I., Sester, M., Gomez-Reino, J. J., Rieder, H. L., Ehlers, S., Milburn, H. J., Kampmann, B., Hellmich, B., Groves, R., Schreiber, S., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00028510 · Cited by 527
Gerfaud-Valentin, M., Jamilloux, Y., Iwaz, J., & Sève, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.058 · Cited by 518
A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients
Emsley, H. C. A. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.054882 · Cited by 445
Inflammatory markers and the risk of Alzheimer disease: The Framingham Study
Tan, Z. S., Beiser, A. S., Vasan, R. S., Roubenoff, R., Dinarello, C. A., Harris, T. B., Benjamin, E. J., Au, R., Kiel, D. P., Wolf, P. A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000263217.36439.da · Cited by 440
Self-citationTumor necrosis factor-alpha and interleukin-1 beta synergistically depress human myocardial function
Cain, B. S., Meldrum, D. R., Dinarello, C. A., Meng, X., Joo, K. S., Banerjee, A., & Harken, A. H. (1999) · Critical Care Medicine · doi:10.1097/00003246-199907000-00018 · Cited by 421
Self-citationAbbate, A., Kontos, M. C., Grizzard, J. D., Biondi-Zoccai, G. G. L., Van Tassell, B. W., Robati, R., Roach, L. M., Arena, R. A., Roberts, C. S., Varma, A., et al. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.12.059 · Cited by 415
Self-citationAn Autoinflammatory Disease Due to Homozygous Deletion of the IL1RN Locus
Reddy, S., Jia, S., Geoffrey, R., Lorier, R., Suchi, M., Broeckel, U., Hessner, M. J., & Verbsky, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809568 · Cited by 411
Pathogenesis of Macrophage Activation Syndrome and Potential for Cytokine- Directed Therapies
Schulert, G. S., & Grom, A. A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-061813-012806 · Cited by 402
Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes
Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., & Mandrup-Poulsen, T. (2009) · Diabetes Care · doi:10.2337/dc09-0533 · Cited by 401
Brucato, A., Imazio, M., Gattorno, M., Lazaros, G., Maestroni, S., Carraro, M., Finetti, M., Cumetti, D., Carobbio, A., Ruperto, N., et al. (2016) · JAMA · doi:10.1001/jama.2016.15826 · Cited by 401
Abbate, A., Van Tassell, B. W., Biondi-Zoccai, G., Kontos, M. C., Grizzard, J. D., Spillman, D. W., Oddi, C., Roberts, C. S., Melchior, R. D., Mueller, G. H., et al. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.01.287 · Cited by 393
Self-citationFleischmann, R. M., Schechtman, J., Bennett, R., Handel, M. L., Burmester, G., Tesser, J., Modafferi, D., Poulakos, J., & Sun, G. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10870 · Cited by 392
Gattorno, M., Piccini, A., Lasigliè, D., Tassi, S., Brisca, G., Carta, S., Delfino, L., Ferlito, F., Pelagatti, M. A., Caroli, F., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23437 · Cited by 382
Aganna, E., Martinon, F., Hawkins, P. N., Ross, J. B., Swan, D. C., Booth, D. R., Lachmann, H. J., Gaudet, R., Woo, P., Feighery, C., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10509 · Cited by 367
Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition
Canna, S. W., Girard, C., Malle, L., de Jesus, A., Romberg, N., Kelsen, J., Surrey, L. F., Russo, P., Sleight, A., Schiffrin, E., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.10.022 · Cited by 366
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller‐Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15318 · Cited by 363
Vezzani, A., Maroso, M., Balosso, S., Sanchez, M.-A., & Bartfai, T. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.03.018 · Cited by 362
Moran, A., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Greenbaum, C. J., Herold, K. C., Marks, J. B., Raskin, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60023-9 · Cited by 356
Morton, A. C., Rothman, A. M. K., Greenwood, J. P., Gunn, J., Chase, A., Clarke, B., Hall, A. S., Fox, K., Foley, C., Banya, W., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu272 · Cited by 353
Rapid responses to anakinra in patients with refractory adult‐onset Still's disease
Fitzgerald, A. A., LeClercq, S. A., Yan, A., Homik, J. E., & Dinarello, C. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21061 · Cited by 350
Self-citationA urine inhibitor of interleukin 1 activity that blocks ligand binding.
Seckinger, P., Lowenthal, J. W., Williamson, K., Dayer, J. M., & MacDonald, H. R. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.5.1546 · Cited by 345
Anakinra for Rheumatoid Arthritis: A Systematic Review
MERTENS, M., & SINGH, J. A. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090074 · Cited by 344
Increased Plasma Interleukin-1 Activity in Women After Ovulation
Cannon, J. G., & Dinarello, C. A. (1985) · Science · doi:10.1126/science.3871966 · Cited by 340
Self-citationAnti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
Everett, B. M., Donath, M. Y., Pradhan, A. D., Thuren, T., Pais, P., Nicolau, J. C., Glynn, R. J., Libby, P., & Ridker, P. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.002 · Cited by 329
Joosten, L. A. B., Netea, M. G., Mylona, E., Koenders, M. I., Malireddi, R. K. S., Oosting, M., Stienstra, R., van de Veerdonk, F. L., Stalenhoef, A. F., Giamarellos‐Bourboulis, E. J., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27667 · Cited by 328
Arend, W. P., Joslin, F. G., & Massoni, R. J. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.134.6.3868 · Cited by 322
Braun‐Falco, M., Kovnerystyy, O., Lohse, P., & Ruzicka, T. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.12.025 · Cited by 318
Gattorno, M., Pelagatti, M. A., Meini, A., Obici, L., Barcellona, R., Federici, S., Buoncompagni, A., Plebani, A., Merlini, G., & Martini, A. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23475 · Cited by 312
Production of interleukin-1-receptor antagonist during experimental endotoxaemia
Granowitz, E. V., Poutsiaka, D. D., Cannon, J. G., Wolff, S. M., Dinarello, C. A., Santos, A. A., & Wilmore, D. W. (1991) · The Lancet · doi:10.1016/0140-6736(91)92725-h · Cited by 310
Self-citationPomerantz, B. J., Reznikov, L. L., Harken, A. H., & Dinarello, C. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041611398 · Cited by 310
Self-citationIkonomidis, I., Lekakis, J. P., Nikolaou, M., Paraskevaidis, I., Andreadou, I., Kaplanoglou, T., Katsimbri, P., Skarantavos, G., Soucacos, P. N., & Kremastinos, D. T. (2008) · Circulation · doi:10.1161/circulationaha.107.731877 · Cited by 307
Safety of extended treatment with anakinra in patients with rheumatoid arthritis
Fleischmann, R. M., Tesser, J., Schiff, M. H., Schechtman, J., Burmester, G.-R., Bennett, R., Modafferi, D., Zhou, L., Bell, D., & Appleton, B. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.048371 · Cited by 305
Joosten, L. A. B., Netea, M. G., Fantuzzi, G., Koenders, M. I., Helsen, M. M. A., Sparrer, H., Pham, C. T., van der Meer, J. W. M., Dinarello, C. A., & van den Berg, W. B. (2009) · Arthritis & Rheumatism · doi:10.1002/art.25006 · Cited by 296
Self-citationHernandez-Rodriguez, J. (2003) · Rheumatology · doi:10.1093/rheumatology/keh058 · Cited by 295
Stojanov, S., Lapidus, S., Chitkara, P., Feder, H., Salazar, J. C., Fleisher, T. A., Brown, M. R., Edwards, K. M., Ward, M. M., Colbert, R. A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103681108 · Cited by 294
Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes
Cavelti-Weder, C., Babians-Brunner, A., Keller, C., Stahel, M. A., Kurz-Levin, M., Zayed, H., Solinger, A. M., Mandrup-Poulsen, T., Dinarello, C. A., & Donath, M. Y. (2012) · Diabetes Care · doi:10.2337/dc11-2219 · Cited by 294
Self-citationRoburn, M. (1964) · PubMed · Cited by 292
Suppression of inflammation and acquired immunity by IL‐37
Cavalli, G., & Dinarello, C. A. (2018) · Immunological Reviews · doi:10.1111/imr.12605 · Cited by 291
Self-citationSevere imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome
Mazodier, K. (2005) · Blood · doi:10.1182/blood-2005-05-1980 · Cited by 290
Antagonism of peripheral inflammation reduces the severity of status epilepticus
Marchi, N., Fan, Q., Ghosh, C., Fazio, V., Bertolini, F., Betto, G., Batra, A., Carlton, E., Najm, I., Granata, T., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.002 · Cited by 284
Grom, A. A., Villanueva, J., Lee, S., Goldmuntz, E. A., Passo, M. H., & Filipovich, A. (2003) · The Journal of Pediatrics · doi:10.1067/mpd.2003.110 · Cited by 284
Miettunen, P. M., Narendran, A., Jayanthan, A., Behrens, E. M., & Cron, R. Q. (2011) · Rheumatology · doi:10.1093/rheumatology/keq218 · Cited by 284
Singh, N., Hopkins, S. J., Hulme, S., Galea, J. P., Hoadley, M., Vail, A., Hutchinson, P. J., Grainger, S., Rothwell, N. J., King, A. T., et al. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-1 · Cited by 284
A NOVEL IL-18BP ELISA SHOWS ELEVATED SERUM IL-18BP IN SEPSIS AND EXTENSIVE DECREASE OF FREE IL-18
Novick, D., Schwartsburd, B., Pinkus, R., Suissa, D., Belzer, I., Sthoeger, Z., Keane, W. F., Chvatchko, Y., Kim, S.-H., Fantuzzi, G., et al. (2001) · Cytokine · doi:10.1006/cyto.2001.0914 · Cited by 277
Self-citationHuman leukocytic pyrogen: purification and development of a radioimmunoassay.
Dinarello, C. A., Renfer, L., & Wolff, S. M. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.10.4624 · Cited by 272
Self-citationSafety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial
Tzanetakou, V., Kanni, T., Giatrakou, S., Katoulis, A., Papadavid, E., Netea, M. G., Dinarello, C. A., van der Meer, J. W. M., Rigopoulos, D., & Giamarellos-Bourboulis, E. J. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.3903 · Cited by 266
Self-citationNeven, B., Marvillet, I., Terrada, C., Ferster, A., Boddaert, N., Couloignier, V., Pinto, G., Pagnier, A., Bodemer, C., Bodaghi, B., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.25057 · Cited by 265
Febrile infection‐related epilepsy syndrome treated with anakinra
Kenney‐Jung, D. L., Vezzani, A., Kahoud, R. J., LaFrance‐Corey, R. G., Ho, M., Muskardin, T. W., Wirrell, E. C., Howe, C. L., & Payne, E. T. (2016) · Annals of Neurology · doi:10.1002/ana.24806 · Cited by 265
Kanemoto, K., Kawasaki, J., Miyamoto, T., Obayashi, H., & Nishimura, M. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200005)47:5<571::aid-ana3>3.0.co;2-a · Cited by 263
Vastert, S. J., de Jager, W., Noordman, B. J., Holzinger, D., Kuis, W., Prakken, B. J., & Wulffraat, N. M. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38296 · Cited by 258
Gattorno, M., Tassi, S., Carta, S., Delfino, L., Ferlito, F., Pelagatti, M. A., D'Osualdo, A., Buoncompagni, A., Alpigiani, M. G., Alessio, M., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22842 · Cited by 247
Cohen, S. B., Proudman, S., Kivitz, A. J., Burch, F. X., Donohue, J. P., Burstein, D., Sun, Y.-N., Banfield, C., Vincent, M. S., Ni, L., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3430 · Cited by 246
Van Tassell, B. W., Canada, J., Carbone, S., Trankle, C., Buckley, L., Oddi Erdle, C., Abouzaki, N. A., Dixon, D., Kadariya, D., Christopher, S., et al. (2017) · Circulation: Heart Failure · doi:10.1161/circheartfailure.117.004373 · Cited by 245
Aróstegui, J. I., Arnal, C., Merino, R., Modesto, C., Antonia Carballo, M., Moreno, P., García‐Consuegra, J., Naranjo, A., Ramos, E., de Paz, P., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22966 · Cited by 238
Differences in signaling pathways by IL-1β and IL-18
Lee, J.-K., Kim, S.-H., Lewis, E. C., Azam, T., Reznikov, L. L., & Dinarello, C. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402800101 · Cited by 237
Self-citationVan Tassell, B. W., Arena, R. A., Toldo, S., Mezzaroma, E., Azam, T., Seropian, I. M., Shah, K., Canada, J., Voelkel, N. F., Dinarello, C. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033438 · Cited by 232
Self-citationDEMONSTRATION AND CHARACTERIZATION OF TWO DISTINCT HUMAN LEUKOCYTIC PYROGENS
Dinarello, C. A., Goldin, N. P., & Wolff, S. M. (1974) · The Journal of Experimental Medicine · doi:10.1084/jem.139.6.1369 · Cited by 229
Self-citationBrenner, M., Ruzicka, T., Plewig, G., Thomas, P., & Herzer, P. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09404.x · Cited by 225
Kuemmerle-Deschner, J. B., Hachulla, E., Cartwright, R., Hawkins, P. N., Tran, T. A., Bader-Meunier, B., Hoyer, J., Gattorno, M., Gul, A., Smith, J., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.152728 · Cited by 222
Pathogenesis of hemophagocytic syndrome (HPS)
Larroche, C., & Mouthon, L. (2004) · Autoimmunity Reviews · doi:10.1016/s1568-9972(03)00091-0 · Cited by 221
Sibley, C. H., Plass, N., Snow, J., Wiggs, E. A., Brewer, C. C., King, K. A., Zalewski, C., Kim, H. J., Bishop, R., Hill, S., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34409 · Cited by 220
Macrophage activation syndrome: advances towards understanding pathogenesis
Grom, A. A., & Mellins, E. D. (2010) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000381996.69261.71 · Cited by 211
Meinzer, U., Quartier, P., Alexandra, J.-F., Hentgen, V., Retornaz, F., & Koné-Paut, I. (2011) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2010.11.003 · Cited by 205
Balavoine, J. F., de Rochemonteix, B., Williamson, K., Seckinger, P., Cruchaud, A., & Dayer, J. M. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112669 · Cited by 205
Efficacy of anti-IL-1 treatment in Majeed syndrome
Herlin, T., Fiirgaard, B., Bjerre, M., Kerndrup, G., Hasle, H., Bing, X., & Ferguson, P. J. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201818 · Cited by 200
Anakinra for flares of pyogenic arthritis in PAPA syndrome
Dierselhuis, M. P. (2005) · Rheumatology · doi:10.1093/rheumatology/keh479 · Cited by 200
Rajasekaran, S., Kruse, K., Kovey, K., Davis, A. T., Hassan, N. E., Ndika, A. N., Zuiderveen, S., & Birmingham, J. (2014) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000000078 · Cited by 198
Chevalier, X., Giraudeau, B., Conrozier, T., Marliere, J., Kiefer, P., & Goupille, P. (2005) · PubMed · Cited by 197
Ruperto, N., Quartier, P., Wulffraat, N., Woo, P., Ravelli, A., Mouy, R., Bader‐Meunier, B., Vastert, S. J., Noseda, E., D'Ambrosio, D., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33342 · Cited by 196
Interleukin-1 blockade in cardiovascular diseases: a clinical update
Buckley, L. F., & Abbate, A. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy128 · Cited by 194
Cavalli, G., Guglielmi, B., Berti, A., Campochiaro, C., Sabbadini, M. G., & Dagna, L. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202542 · Cited by 193
Self-citationAukrust, P., Froland, S., Liabakk, N., Muller, F., Nordoy, I., Haug, C., & Espevik, T. (1994) · Blood · doi:10.1182/blood.v84.7.2136.2136 · Cited by 191
Sloan-Lancaster, J., Abu-Raddad, E., Polzer, J., Miller, J. W., Scherer, J. C., De Gaetano, A., Berg, J. K., & Landschulz, W. H. (2013) · Diabetes Care · doi:10.2337/dc12-1835 · Cited by 184
Rosenwasser, L. J., Dinarello, C. A., & Rosenthal, A. S. (1979) · The Journal of experimental medicine · doi:10.1084/jem.150.3.709 · Cited by 183
Self-citationHelmy, A., Guilfoyle, M. R., Carpenter, K. L., Pickard, J. D., Menon, D. K., & Hutchinson, P. J. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.23 · Cited by 182
Anakinra for rheumatoid arthritis
Mertens, M., & Singh, J. A. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005121.pub3 · Cited by 179
Kuemmerle-Deschner, J. B., Tyrrell, P. N., Koetter, I., Wittkowski, H., Bialkowski, A., Tzaribachev, N., Lohse, P., Koitchev, A., Deuter, C., Foell, D., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30149 · Cited by 177
Norheim, K. B., Harboe, E., Gøransson, L. G., & Omdal, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030123 · Cited by 176
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies
Cavalli, G., & Dinarello, C. A. (2015) · Rheumatology · doi:10.1093/rheumatology/kev269 · Cited by 171
Self-citationRobertson, M. J., Mier, J. W., Logan, T., Atkins, M., Koon, H., Koch, K. M., Kathman, S., Pandite, L. N., Oei, C., Kirby, L. C., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0121 · Cited by 170
On-demand anakinra treatment is effective in mevalonate kinase deficiency
Bodar, E. J., Kuijk, L. M., Drenth, J. P. H., van der Meer, J. W. M., Simon, A., & Frenkel, J. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.149922 · Cited by 168
van Asseldonk, E. J. P., Stienstra, R., Koenen, T. B., Joosten, L. A. B., Netea, M. G., & Tack, C. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2992 · Cited by 165
Beneficial response to interleukin 1 receptor antagonist in traps
Simon, A., Bodar, E. J., van der Hilst, J. C. H., van der Meer, J. W. M., Fiselier, T. J. W., Cuppen, M. P. J. M., & Drenth, J. P. H. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.02.039 · Cited by 164
New Insights in the Immunobiology of IL-1 Family Members
van de Veerdonk, F. L., & Netea, M. G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00167 · Cited by 163
Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood
Eleftheriou, D., Gerschman, T., Sebire, N. J., Woo, P. M., Pilkington, C., & Brogan, P. A. (2010) · Rheumatology · doi:10.1093/rheumatology/keq122 · Cited by 157
Picco, P. P., Brisca, G., Traverso, F., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.24174 · Cited by 156
Inflammasome and IL-1β-Mediated Disorders
Hoffman, H. M., & Wanderer, A. A. (2010) · Current Allergy and Asthma Reports · doi:10.1007/s11882-010-0109-z · Cited by 154
Alten, R., Gómez-Reino, J. J., Durez, P., Beaulieu, A. D., Sebba, A. I., Krammer, G., Preiss, R., Arulmani, U., Widmer, A., Gitton, X., et al. (2011) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-12-153 · Cited by 154
Specific gene expression profiles in systemic juvenile idiopathic arthritis
Ogilvie, E. M., Khan, A., Hubank, M. J. F., Kellam, P., & Woo, P. M. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22644 · Cited by 151
Campochiaro, C., Tomelleri, A., Cavalli, G., Berti, A., & Dagna, L. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.03.004 · Cited by 151
Self-citationMacrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities?
Grom, A. A. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200309000-00011 · Cited by 148
A case of macrophage activation syndrome successfully treated with anakinra
Kelly, A., & Ramanan, A. V. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0919 · Cited by 147
Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra
McGonagle, D. G., Tan, A. L., Shankaranarayana, S., Madden, J. M., Emery, P., & McDermott, M. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.073759 · Cited by 146
Rationale and efficacy of interleukin-1 targeting in Erdheim–Chester disease
Aouba, A., Georgin‐Lavialle, S., Pagnoux, C., Silva, N. M., Renand, A., Galateau-Sallé, F., Toquin, S. L., Bensadoun, H., Larousserie, F., Silvera, S., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279240 · Cited by 144
Ilowite, N. T., Porras, Ó., Reiff, A. O., Rudge, S., Punaro, M., Martin, A. A., Allen, R. C., Harville, T., Sun, Y.-N., Bevirt, T., et al. (2008) · Clinical Rheumatology · doi:10.1007/s10067-008-0995-9 · Cited by 143
Rissanen, A., Howard, C. P., Botha, J., Thuren, T. Y., & for the Global Investigators (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01637.x · Cited by 143
IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus
Peiró, C., Lorenzo, Ó., Carraro, R., & Sánchez‐Ferrer, C. F. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00363 · Cited by 142
Interleukin-18 mediates interleukin-1-induced cardiac dysfunction
Toldo, S. A., Mezzaroma, E., O’Brien, L. C., Marchetti, C., Seropian, I. M., Voelkel, N. F., Tassell, B. W. V., Dinarello, C. A., & Abbate, A. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00795.2013 · Cited by 141
Self-citationMarzano, A. V., Ishak, R. S., Saibeni, S., CROSTI, C., Meroni, P. L., & Cugno, M. (2013) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-012-8351-x · Cited by 140
Opposing Functions of Classic and Novel IL-1 Family Members in Gut Health and Disease
Lopetuso, L. R., Chowdhry, S., & Pizarro, T. T. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00181 · Cited by 139
Tassell, B. W. V., Abouzaki, N. A., Oddi, C., Carbone, S., Trankle, C. R., Melchior, R. D., Turlington, J., Thurber, C. J., Christopher, S., Dixon, D. L., et al. (2016) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000378 · Cited by 138
Self-citationLong-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes
Kullenberg, T., Löfqvist, M., Leinonen, M., Goldbach‐Mansky, R. T., & Olivecrona, H. (2016) · Rheumatology · doi:10.1093/rheumatology/kew208 · Cited by 138
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
Singh, J. A., Christensen, R., Wells, G. A., Suarez-Almazor, M. E., Buchbinder, R., Lopez-Olivo, M. A., Ghogomu, E. T., & Tugwell, P. (2010) · Sao Paulo Medical Journal · doi:10.1590/s1516-31802010000500013 · Cited by 137
Induction of circulating IL-1 receptor antagonist by IFN treatment
Tilg, H., Mier, J. W., Vogel, W., Aulitzky, W. E., Wiedermann, C. J., Vannier, E. G., Huber, C. H., & Dinarello, C. A. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.10.4687 · Cited by 136
Self-citationDinarello, C. A., Rosenwasser, L. J., & Wolff, S. (1981) · The Journal of Immunology · doi:10.4049/jimmunol.127.6.2517 · Cited by 132
Self-citationAmparo, F., Dastjerdi, M. H., Okanobo, A., Ferrari, G., Smaga, L., Hamrah, P., Jurkunas, U. V., Schaumberg, D. A., & Dana, R. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.195 · Cited by 132
Moser, C. E., Pohl, G., Haslinger, I., Knapp, S., Rowczenio, D. M., Russel, T., Lachmann, H. J., Lang, U., & Kovarik, J. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn646 · Cited by 132
Current Status of Understanding the Pathogenesis and Management of Patients With NOMID/CINCA
Goldbach‐Mansky, R. T. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-011-0165-y · Cited by 131
Kawasaki disease shock syndrome: Unique and severe subtype of Kawasaki disease
Gámez‐González, L. B., Moribe-Quintero, I. C., Cisneros-Castólo, M., Ortiz, J. V., Muñoz-Ramírez, M. C., Garrido‐García, L. M., & Yamazaki‐Nakashimada, M. A. (2018) · Pediatrics International · doi:10.1111/ped.13614 · Cited by 130
Galea, J. P., Ogungbenro, K., Hulme, S., Greenhalgh, A. D., Aarons, L. J., Scarth, S., Hutchinson, P. J., Grainger, S., King, A. T., Hopkins, S. J., et al. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.103 · Cited by 128
de Koning, H. D., van Gijn, M. E., Stoffels, M., van der Ven‐Jongekrijg, J., Zeeuwen, P. L. J. M., Elferink, M., Nijman, I. J., Jansen, P. A. M., Neveling, K., van der Meer, J. W. M., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.07.050 · Cited by 128
Clark, S., McMahon, C. J., Gueorguieva, I., Rowland, M., Scarth, S., Georgiou, R. F., Tyrrell, P. J., Hopkins, S. J., & Rothwell, N. J. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600537 · Cited by 124
Koné‐Paut, I., Cimaz, R., Herberg, J. A., Bates, O., Carbasse, A., Saulnier, J. P., Maggio, M. C., Antón, J., & Piram, M. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.01.024 · Cited by 124
Prieur, A., Griscelli, C., Kaufmann, M., & Dayer, J. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91854-x · Cited by 122
Successful treatment of resistant pseudogout with anakinra
McGonagle, D. G., Tan, A. L., Madden, J. M., Emery, P., & McDermott, M. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23119 · Cited by 121
Sönmez, H. E., Demir, S., Bilginer, Y., & Özen, S. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4095-1 · Cited by 119
The role of interleukin-1β in febrile seizures
Heida, J. G., Moshé, S. L., & Pittman, Q. J. (2009) · Brain and Development · doi:10.1016/j.braindev.2008.11.013 · Cited by 116
IL-1β, IL-6 and IL1Ra levels in temporal lobe epilepsy
Uludağ, İ. F., Duksal, T., Tiftikçioğlu, B. İ., Zorlu, Y., Ozkaya, F., & Kırkalı, G. (2015) · Seizure · doi:10.1016/j.seizure.2015.01.009 · Cited by 115
Lepore, L., Paloni, G., Caorsi, R., Alessio, M., Rigante, D., Ruperto, N., Cattalini, M., Tommasini, A., Zulian, F., Ventura, A., et al. (2010) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2010.02.040 · Cited by 114
Cangi, M. G., Biavasco, R., Cavalli, G., Grassini, G., Dal-Cin, E., Campochiaro, C., Guglielmi, B., Berti, A., Lampasona, V., von Deimling, A., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204924 · Cited by 112
Self-citationCavalli, G., Justice, J. N., Boyle, K. E., D’Alessandro, A., Eisenmesser, E. Z., Herrera, J. J., Hansen, K. C., Nemkov, T. G., Stienstra, R., Garlanda, C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619011114 · Cited by 112
Self-citationde Koning, H. D., Schalkwijk, J., van der Ven‐Jongekrijg, J., Stoffels, M., van der Meer, J. W. M., & Simon, A. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202192 · Cited by 111
Stankovic, K., Delmas, Y., Ureña, P., Peltier, J., Pellé, G., Jéru, I., Colombat, M., & Grateau, G. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr528 · Cited by 110
Kamari, Y., Werman-Venkert, R., Shaish, A., Werman, A., Harari, A., Gonen, A., Voronov, E., Grosskopf, I., Sharabi, Y., Grossman, E., et al. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.11.026 · Cited by 109
Self-citationToldo, S. A., Mezzaroma, E., Tassell, B. W. V., Farkas, D., Marchetti, C., Voelkel, N. F., & Abbate, A. (2012) · Experimental Physiology · doi:10.1113/expphysiol.2012.069831 · Cited by 109
Cavalli, G., Koenders, M. I., Kalabokis, V., Kim, J., Tan, A. C., Garlanda, C., Mantovani, A., Dagna, L., Joosten, L. A. B., & Dinarello, C. A. (2016) · Rheumatology · doi:10.1093/rheumatology/kew325 · Cited by 108
Self-citationCantarini, L., Lucherini, O. M., Muscari, I., Frediani, B., Galeazzi, M., Brizi, M. G., Simonini, G., & Cimaz, R. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.07.020 · Cited by 106
Hidradenitis Suppurativa and Concomitant Pyoderma Gangrenosum
Hsiao, J. L., Antaya, R. J., Berger, T. G., Maurer, T. A., Shinkai, K., & Leslie, K. S. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2010.328 · Cited by 106
Cavalli, G., Hayashi, M., Jin, Y., Yorgov, D., Santorico, S. A., Holcomb, C. L., Rastrou, M. V., Erlich, H., Tengesdal, I. W., Dagna, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1523482113 · Cited by 106
Self-citationMolecular genetics of febrile seizures
Nakayama, J., & Arinami, T. (2006) · Epilepsy Research · doi:10.1016/j.eplepsyres.2005.11.023 · Cited by 105
Colafrancesco, S., Priori, R., Valesini, G., Argolini, L. M., Baldissera, E. M., Bartoloni, E., Cammelli, D., Canestrari, G. B., Cantarini, L., Cavallaro, E. C., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00369 · Cited by 105
Self-citationSystemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade
DeSena, A. D., Do, T., & Schulert, G. S. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1063-2 · Cited by 105
Pathak, S., Goldofsky, E., Vivas, E. X., Bonagura, V. R., & Vambutas, A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002275 · Cited by 99
Sümegi, J., Barnes, M., Nestheide, S. V., Molleran-Lee, S., Villanueva, J. M., Zhang, K., Risma, K., Grom, A. A., & Filipovich, A. H. (2011) · Blood · doi:10.1182/blood-2010-08-300046 · Cited by 98
Kluger, N., Gil-Bistes, D., Guillot, B., & Bessis, D. (2011) · Dermatology · doi:10.1159/000326112 · Cited by 97
Treating Life-Threatening Myocarditis by Blocking Interleukin-1*
Cavalli, G., Pappalardo, F., Mangieri, A., Dinarello, C. A., Dagna, L., & Tresoldi, M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001654 · Cited by 96
Self-citationCryopyrin‐Associated Periodic Syndromes
Ahmadi, N., Brewer, C. C., Zalewski, C. K., King, K. A., Butman, J. A., Plass, N., Henderson, C., Goldbach‐Mansky, R. T., & Kim, H. J. (2011) · Otolaryngology · doi:10.1177/0194599811402296 · Cited by 93
Maeno, N., Takei, S., Imanaka, H., Yamamoto, K., Kuriwaki, K., Kawano, Y., & Oda, H. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20268 · Cited by 91
Vitale, A., Insalaco, A., Sfriso, P., Lopalco, G., Emmi, G., Cattalini, M., Manna, R., Cimaz, R., Priori, R., Talarico, R., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00380 · Cited by 91
Cantarini, L., Lopalco, G., Caso, F., Costa, L., Iannone, F., Lapadula, G., Anelli, M. G., Franceschini, R., Menicacci, C., Galeazzi, M., et al. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.08.008 · Cited by 89
Colina, M., Pizzirani, C., Khodeir, M., Falzoni, S., Bruschi, M., Trotta, F., & Virgilio, F. D. (2010) · Rheumatology · doi:10.1093/rheumatology/keq074 · Cited by 89
Rynne, M., Maclean, C., Bybee, A., McDermott, M. F., & Emery, P. E. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.038091 · Cited by 86
Reimers, A., Fux, C., & Spaeth, P. (2002) · Swiss Medical Weekly · doi:10.4414/smw.2002.09941 · Cited by 85
Neurologic manifestations of the cryopyrin-associated periodic syndrome
Kitley, J., Lachmann, H. J., Pinto, A. A., & Ginsberg, L. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d9ed69 · Cited by 83
Interleukin-6, interleukin-1 beta and interleukin-1 receptor antagonist levels in epileptic seizures
Uludağ, İ. F., Bilgin, Ş., Zorlu, Y., Tuna, G., & Kırkalı, G. (2013) · Seizure · doi:10.1016/j.seizure.2013.03.004 · Cited by 80
Myocarditis: An Interleukin-1-Mediated Disease?
De Luca, G., Cavalli, G., Campochiaro, C., Tresoldi, M., & Dagna, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01335 · Cited by 79
Self-citationEarly efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease
Vambutas, A., LESSER, M. L., Mullooly, V. M., Pathak, S., Zahtz, G. D., Rosen, L., & Goldofsky, E. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76503 · Cited by 78
Erosive osteoarthritis of the hand: clinical experience with anakinra
Bacconnier, L., Jørgensen, C., & Fabre, S. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.094284 · Cited by 77
Böni‐Schnetzler, M., Häuselmann, S. P., Dalmas, É., Meier, D. T., Thienel, C., Traub, S., Schulze, F., Steiger, L., Dror, E., Martin, P., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.063 · Cited by 77
Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens
Kuemmerle-Deschner, J. B., Wittkowski, H., Tyrrell, P. N., Koetter, I., Lohse, P., Ummenhofer, K., Reess, F., Hansmann, S., Koitschev, A., Deuter, C., et al. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4237 · Cited by 75
Behrens, E. M., Kreiger, P. A., Cherian, S., & Cron, R. Q. (2006) · PubMed · Cited by 75
Announ, N., Palmer, G., Guerne, P., & Gabay, C. (2009) · Joint Bone Spine · doi:10.1016/j.jbspin.2009.01.001 · Cited by 74
Successful Treatment of Severe Hidradenitis Suppurativa With Anakinra
Zarchi, K., Dufour, D., & Jemec, G. B. E. (2013) · JAMA Dermatology · doi:10.1001/jamadermatol.2013.5377 · Cited by 73
Harrison, S. R., McGonagle, D., Nizam, S., Jarrett, S. J., van der Hilst, J. C. H., McDermott, M., & Savic, S. (2016) · JCI Insight · doi:10.1172/jci.insight.86336 · Cited by 73
Efficacy and safety of biological agents in adult-onset Still’s disease
Cavalli, G., Franchini, S., Aiello, P., Guglielmi, B., Berti, A., Campochiaro, C., Sabbadini, M. G., Baldissera, E. M., & Dagna, L. (2015) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2014.992949 · Cited by 72
Self-citationEffect of interleukin-18 on mouse core body temperature
Gatti, S., Beck, J., Fantuzzi, G., Bartfai, T., & Dinarello, C. A. (2002) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00393.2001 · Cited by 72
Self-citationInterleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure
Cavalli, G., Foppoli, M., Cabrini, L., Dinarello, C. A., Tresoldi, M., & Dagna, L. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00131 · Cited by 70
Self-citationHydrocephalus in CINCA syndrome treated with anakinra
Rigante, D., Ansuini, V., Caldarelli, M., Bertoni, B., Torraca, I. L., & Stabile, A. (2006) · Child s Nervous System · doi:10.1007/s00381-006-1280-3 · Cited by 70
Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome
Delluc, A., Limal, N., Puéchal, X., Francès, C., Pietté, J. C., & Cacoub, P. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.068254 · Cited by 69
Primdahl, J., Clausen, J., & Hørslev‐Petersen, K. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203682 · Cited by 68
The history of fever, leukocytic pyrogen and interleukin-1
Dinarello, C. A. (2015) · Temperature · doi:10.1080/23328940.2015.1017086 · Cited by 62
Self-citation
Cited by
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Endometriosis: Etiology, pathobiology, and therapeutic prospects
Saunders, P. T. K., & Horne, A. W. (2021) · Cell · doi:10.1016/j.cell.2021.04.041 · Cited by 961
Bonnardel, J., T’Jonck, W., Gaublomme, D., Browaeys, R., Scott, C. L., Martens, L., Vanneste, B., De Prijck, S., Nedospasov, S. A., Kremer, A., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.017 · Cited by 631
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
Gressler, M., Heddergott, C., N'Go, I. C., Renga, G., Oikonomou, V., Moretti, S., Coddeville, B., Gaifem, J., Silvestre, R., Romani, L., et al. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00365 · Cited by 27
Metadata
- Authors
- Cavalli, G., & Dinarello, C. A.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-11-06
- Volume
- 9
- Pages
- 1157-1157
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2899747393
- Cited by
- 292
- References
- 244
- FWCI
- 10.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.